What is CF?
Real Facts for You
Did you know that over 1000 mutations in the CFTR gene can lead to cystic fibrosis?Learn More
Join a Study
Finding Solutions Together
Participate in a research study of new cystic fibrosis therapies at Johns Hopkins.Learn More
Follow Us on Twitter @HopkinsCF
- FDA approves new treatment for cystic fibrosis http://t.co/Pz7Adz4aWx
- FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of... | Business Wire http://t.co/EgUhHJJ0ve
- Laurent Pharmaceuticals Announces Positive Data from Recent Phase 1 Cystic Fibrosis Trial http://t.co/ijzPUFi6AA
Find Us on Facebook
Exercise Study Is Now Enrolling
We are now enrolling adolescents and young adults from the Johns Hopkins CF Center who have cystic fibrosis for a research study to evaluate an outpatient fitness-training program called Do More, B’More, Live Fit. Get more information.
- Webcast on Lung Infection in CF Is Available Online Now
New Lung Function Reference Equations In Use
The pediatric pulmonary function laboratory is now using the Global Lungs Initiative reference equations for predicted values.
Ivacaftor Approved for Young Children with CF
Vertex Received U.S. Food and Drug Administration Approval of KALYDECO® (ivacaftor) for Children with Cystic Fibrosis Ages 2 to 5 who have Specific Mutations in the CFTR Gene. See the press release.
New Issue of eCystic Fibrosis Review Is Available
Check out the latest issue of eCF Review on Improving digestive capabilities in nutritionally compromised patients with CF authored by Steven Freedman, MD, PhD, Professor of Medicine at Harvard University.
Hopkins CF Newsletter: Partners in Discovery
Issue: Winter 2015
The Transition: As the average life expectancy of patients with CF has risen dramatically over the past 20 years, more and more patients are living on their own, attending college and pursuing careers. DOWNLOAD PDF | SIGN-UP
Family Day Presentations Are Available Online
The recorded webcast of our Annual Johns Hopkins CF Center Family Education Day is now available. Dr. Michael Boyle was our keynote speaker. His presentation was entitled The Journey to Delivering Transformational CF Therapeutics.